Sponsor or institution

Clinical trials and research at Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

• 15Clinical trials
• 1New in 30 days
• 11Countries

Newest trials

All recruiting trials (15)

• How breast radiotherapy technique works best for each patient

  This study tests three radiotherapy plans (3D-CRT, IMRT S&S, and a hybrid) for left breast cancer to see which best fits each patient.

  Recruiting Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Meldola, FC · NCT07881341

• Observational study on triple negative adult B-cell acute lymphoblastic leukemia

  This study looks at adults with triple negative B-cell acute lymphoblastic leukemia to see how genetic changes might affect their treatment and outcomes.

  Recruiting at 3 sites Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Meldola, FC and 2 other locations · NCT06919393

• Using Whole Body MRI to Improve Cancer Detection

  This study is testing if Whole Body MRI can help find bone and soft tissue problems in people with different types of cancer, like lymphoma and advanced prostate and breast cancer.

  Recruiting at 2 sites Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Bologna, BO and 2 other locations · NCT06895291

• Comparing high and low intensity therapies for relapsed or refractory acute myeloid leukemia

  This study is testing whether high-intensity chemotherapy works better than low-intensity treatments for people with relapsed or refractory acute myeloid leukemia.

  Recruiting at 39 sites Phase 3 Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Brno and 50 other locations · NCT06713837

• Combination immunotherapy and chemotherapy for advanced colorectal cancer

  This study is testing a new treatment for patients with advanced colorectal cancer that combines immunotherapy and chemotherapy to see if it can help them better than current options.

  Recruiting Phase 2 Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Meldola, Forlì Cesena and 1 other locations · NCT06522919

• Framework for managing relapsed or refractory acute myeloid leukemia

  This study is trying to see how well new personalized treatments work for people in Europe with relapsed or refractory acute myeloid leukemia to help improve their care.

  Recruiting at 40 sites Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Aachen and 40 other locations · NCT06459024

• Database for patients with bone metastases

  This study is collecting information from adults with bone metastases to help improve understanding and treatment of the condition.

  Recruiting at 29 sites Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Imola, Bologna and 29 other locations · NCT06367491

• Treatment for neuroendocrine tumors using 177Lu-DOTATOC

  This study is testing a new treatment called 177Lu-DOTATOC to see if it can help patients with certain types of neuroendocrine tumors when other treatments aren't working.

  Recruiting Phase 2 Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Cesena, Forlì-Cesena and 1 other locations · NCT06045260

• Combining Lu-PSMA with Stereotactic Radiotherapy for Prostate Cancer Treatment

  This study is testing if combining a targeted prostate cancer treatment with focused radiation can help men with a few small cancer spots feel better and live longer.

  Recruiting at 2 sites Phase 2 Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Cesena, FC and 1 other locations · NCT05893381

• Re-irradiation for women with recurrent breast cancer after previous treatment

  This study is testing a new way to treat women with recurring breast cancer by using targeted radiation again to see if it can help them keep their breast instead of needing surgery.

  Recruiting Phase 2 Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Meldola, Forlì Cesena · NCT05772390

• Treatment for Extensive Stage Small Cell Lung Cancer with Pembrolizumab and Olaparib

  This study is testing a new treatment combining Pembrolizumab and Olaparib to see if it can help people with untreated extensive-stage small cell lung cancer live longer and feel better.

  Recruiting at 9 sites Phase 2 Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Meldola, Forlì Cesena and 11 other locations · NCT05623319

• Analyzing factors for predicting chemotherapy response in gastric cancer

  This study is trying to find out which factors can help predict how well patients with gastric cancer will respond to chemotherapy, so that doctors can better tailor treatments for them.

  Recruiting Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Brest and 4 other locations · NCT04842916

• Determining the best screening interval for breast cancer in women aged 45-49 and 70-74

  This study is trying to find the best timing for breast cancer screenings in women aged 45-49 and 70-74 to help improve recommendations for their care.

  Recruiting at 2 sites Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Meldola (FC), FC and 3 other locations · NCT04590560

• Identifying biomarkers in Diffuse Large B-cell Lymphoma

  This study is trying to find new markers in tissue samples that can help predict how well patients with Diffuse Large B-cell Lymphoma will do over time.

  Recruiting at 4 sites Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Meldola, FC and 3 other locations · NCT04300101

• Vaccination with Dendritic Cells for Patients with Resected Stage IV Rare Cancers

  This study is testing a new vaccine made from patients' own immune cells to see if it can help people who have had rare stage IV cancers feel better and stay healthy after surgery.

  Recruiting Phase 2 Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Meldola, FC · NCT04166006

Quick answers

How many clinical trials run by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS are recruiting right now?

15, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 11 countries. The most sites are in Italy (15 trials), Germany (2 trials), Jordan (2 trials), Lithuania (2 trials), Romania (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 6, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →